Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32676574 | 0.80 | PRMT1 (0.34) | — | |
| SCHEMBL32674353 | 0.80 | RAF1 (0.31) | — | |
| SCHEMBL32674415 | 0.75 | — | — | |
| SCHEMBL30557558 | 0.72 | MAPT (0.49) | MAPTKDM4EALDH1A1POLBKMT2A | |
| SCHEMBL16244909 | 0.72 | MAPT (0.49) | MAPTKDM4EALDH1A1POLBKMT2A | |
| SCHEMBL25366543 | 0.71 | KMT2A (0.48) | MAPTALDH1A1KMT2A | |
| SCHEMBL32674177 | 0.71 | KMT2A (0.39) | ALDH1A1KMT2A | |
| SCHEMBL16972784 | 0.71 | PTGER4 (0.45) | ALDH1A1 | |
| SCHEMBL32681249 | 0.70 | LATS1 (0.32) | MAPTKMT2A | |
| SCHEMBL26107366 | 0.69 | KMT2A (0.52) | MAPTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | OXSR1, JAK1, NCOR1 | MAPT 4260/4885KDM4E 3752/4885ALDH1A1 1726/4885 |
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | NR0B1, NR2C2, ERBB2 | MAPT 4675/4885KDM4E 3246/4885ALDH1A1 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.